Skip to Main Content

Paper Details

Therapeutic Implications of Germline Testing in Patients With Advanced Cancers.
J Clin Oncol
67
2021
ATM, Advanced Cancers, BRCA1, BRCA1/2, BRCA1/2 variants, BRIP1, CHEK2, LP, LP/P, LP/P variant, PALB2, Patients, RAD51C/D, advanced cancer, breast or ovarian, cancer, germline, germline LP/P variant, germline variant, malignancies, metastatic cancer, metastatic or recurrent cancer, mismatch repair genes, patients, poly(ADP-ribose), poly(ADP-ribose) polymerase, predisposition gene, tumor, tumors
Author NameAffiliation
Debyani ChakravartyMemorial Sloan Kettering Cancer Center
Hongxin ZhangMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Ritika KundraMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Michael J MorrisMemorial Sloan Kettering Cancer Center
Wassim AbidaMemorial Sloan Kettering Cancer Center
Michael F WalshMemorial Sloan Kettering Cancer Center
Alexander DrilonMemorial Sloan Kettering Cancer Center
Marc LadanyiMemorial Sloan Kettering Cancer Center
Nikolaus SchultzMemorial Sloan Kettering Cancer Center
Nikolaus SchultzMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Nikolaus SchultzMemorial Sloan Kettering Cancer Center
Nikolaus SchultzMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Michael F BergerMemorial Sloan Kettering Cancer Center
Michael F BergerMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
  • 1 - 14

Datasets

Release 1.2